Following review of data from the U.S. Phase 2 study by the FDA, RedHill plans to expand the global Phase 2/3 study of orally-administered opaganib for severe COVID-19 to the U.S. The study has enrolled over 50% of the targeted 464 patients globally; U.S. ...
The agreements secure high-quality manufacturing capacity of Movantik® for opioid-induced constipation and RHB-204, currently in a Phase 3 study for pulmonary NTM disease Follows recent agreement with Cosmo for expansion of opaganib manufacturing capacity for COVID-19 TEL AVIV, Israel and RALEIGH, ...
- The U.S. Phase 2/3 study with once-daily, orally-administered RHB-107 (upamostat) evaluates treatment of patients with symptomatic COVID-19 who do not require hospitalization - the vast majority of patients - RHB-107 is a novel serine protease inhibitor targeting human cell factors involved in ...
TEL AVIV, Israel and RALEIGH, N.C. , Feb. 9, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will present at the following virtual conferences in February: SVB Leerink 10 th Annual Global ...
Following interim review of unblinded safety and efficacy data, independent DSMB unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib for severe COVID-19 Opaganib targets a human cell component involved in viral replication and is therefore expected to ...
New agreement further expands manufacturing capacity for orally-administered opaganib following positive top-line data from its Phase 2 COVID-19 study, progress with the ongoing global Phase 2/3 study, and amid the urgent need to address emerging viral strains TEL AVIV, Israel and RALEIGH, N.C. ...
TEL AVIV, Israel and RALEIGH, N.C. , Jan. 14, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of its previously announced underwritten offering of 3,188,776 American Depositary Shares (ADSs) ...
TEL AVIV, Israel and RALEIGH, N.C. , Jan. 12, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and ...
TEL AVIV, Israel and RALEIGH, N.C. , Jan. 11, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into an underwriting agreement with H.C. ...
TEL AVIV, Israel and RALEIGH, N.C ,, Jan. 11, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or "the Company"), a specialty biopharmaceutical company, today reported that its partner, Cosmo Pharmaceuticals (SIX: COPN) ("Cosmo"), announced that it had successfully completed ...
Menu